Dimethyl fumarate is currently used in relapsing-remitting multiple sclerosis, but was also found to act against GBM through ERK1/2 and AKT inhibition in GBM cell lines [73]. Here, MAPK3 is linked to relapsing-remitting multiple sclerosis.